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Abstract: The potential importance of both prevention and personal responsibility in   controlling 
heart disease, the leading cause of death in the USA and elsewhere, has attracted renewed 
  attention. Coronary artery disease is preventable, using relatively simple and inexpensive 
lifestyle changes. The inexorable rise in the prevalence of obesity, diabetes, dyslipidemia, 
and   hypertension, often in the risk cluster known as the metabolic syndrome, drives the 
  ever-increasing incidence of heart disease. Population-wide improvements in personal health 
habits appear to be a fundamental, evidence based public health measure, yet numerous bar-
riers prevent i  mplementation. A common symptom in patients with coronary artery disease, 
classical angina refers to the typical chest pressure or discomfort that results when myocardial 
oxygen demand rises and coronary blood flow is reduced by fixed, atherosclerotic, obstructive 
lesions. Different forms of angina and diagnosis, with a short description of the significance of 
pain and silent ischemia, are discussed in this review. The well accepted concept of myocardial 
oxygen imbalance in the genesis of angina is presented with new data about clinical pathology of 
stable angina and acute coronary syndromes. The roles of stress electrocardiography and stress 
myocardial perfusion scintigraphic imaging are reviewed, along with the information these tests 
provide about risk and prognosis. Finally, the current status of gender disparities in heart disease 
is summarized. Enhanced risk stratification and identification of patients in whom procedures 
will meaningfully change management is an ongoing quest. Current guidelines emphasize 
efficient triage of patients with suspected coronary artery disease. Many experts believe the 
predictive value of current decision protocols for coronary artery disease still needs improve-
ment in order to optimize outcomes, yet avoid unnecessary coronary angiograms and radiation 
exposure. Coronary angiography remains the gold standard in the diagnosis of coronary artery 
obstructive disease. Part II of this two part series will address anti-ischemic therapies, new agents, 
cardiovascular risk reduction, options to treat refractory angina, and revascularization.
Keywords: angina, coronary artery disease, ischemic heart disease, myocardial oxygen   balance, 
cardiovascular risk assessment, acute coronary syndrome, electrocardiographic stress testing, 
stress myocardial perfusion imaging, gender disparities in heart disease, silent ischemia, coro-
nary angiography
Introduction
Atherosclerosis and its consequences: coronary artery disease, stroke, peripheral artery 
disease, and aortic and renal arterial disease are modern plagues of   civilization. How-
ever, it should give us pause to learn that atherosclerotic lesions have been   identified 
in 3500-year-old Egyptian mummies,1 with mention of chest pain syndromes in Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
636
Kones
hieroglyphics of papyruses, although certainly this was a 
negligible health concern at that time. Fast forwarding to 
this century, cardiovascular disease is now the most   common 
cause of death, and evidence is now overwhelming that 
our diets and lifestyle are chief causes of obesity, diabetes, 
  dyslipidemia and inflammation leading to atherosclerosis. 
The role of inflammation in etiology and as a potential thera-
peutic target is a topic of intense ongoing interest.2–8
Considerable data show that atherosclerosis and coronary 
artery disease (CAD) are preventable diseases. The data 
further indicate that population-wide dietary changes that 
include a plant-based, calorie controlled intake of fresh, 
whole foods low in sodium and sugar, avoidance of saturated 
and trans fats, together with a higher consumption of omega-3 
fatty acids and perhaps olive oil, combined with adequate 
physical activity, could substantially eliminate the disease.9,10 
Public health implications are compelling, but proven life-
style recommendations remain unheeded.11,12
According to the latest American Heart Association (AHA) 
Statistics 2010,11 overall prevalence of angina is 4.6% in the 
USA, affecting 10,200,000 persons, compared with a total 
number of 17,600,000 patients with CAD. Angina therefore 
afflicts 58% of patients with CAD.11 Approximately 500,000 
new cases are reported yearly, and prevalence rises rapidly with 
increasing age. While anginal attacks are considered reversible 
short term, they are by no means benign, with significant 
morbidity and mortality.13,14 New-onset angina, defined as 
beginning within 2–3 months prior to presentation, has a 
poor prognosis,13,15 with about 10% of patients experiencing 
a nonfatal myocardial infarction or coronary death during the 
next year.16 While much of the data has been collected in men, 
it is now recognized that in women too, angina is not benign, 
with a 19% mortality rate within 4.5 years.17
The expense involved in controlling angina is consider-
able, approaching $1.1 million per capita as a lifetime cost 
in 2006 dollars for women.18 The estimated total direct 
and indirect cost of CAD for 2010 in the United States is 
about $177.1 billion. In weighing statistics, it should be 
emphasized that many millions of people with CAD remain 
undiagnosed, making the numbers, as striking as they are, 
actually conservative.
Definition
Angina, herein referring to angina pectoris, derives from the 
Latin angore, meaning choking and suffocation, but also 
anxiety, fear, or terror. Angina was recognized in the Middle 
Ages, but the description in 1768 by William Heberden is 
far better known.19
Angina is chest discomfort caused by myocardial 
ischemia without necrosis, and is further qualified by its 
precipitating factors, time course to relief, and clinical char-
acteristics, such as radiation and quality. Typical angina may 
be triggered by increased activity (exercise, sex), emotional 
stress (anger, fright, stress), or cold, wind, and fever. The 
discomfort of exertional angina is relieved by rest within 
1–5 min, or more rapidly with sublingual nitroglycerin. 
Episodes last from 2–10 min. Classically there is heaviness 
or pressure retrosternally, with possible radiation to the 
ulnar aspect of the left arm, neck, jaw, mid-abdomen, right 
arm or shoulders. The average frequency of anginal attacks 
in patients is about 2 per week. Many patients voluntarily 
curtail their activities to avoid attacks.
Clinically, angina may be further subdivided according 
to common usage, as follows:
•	 Chronic, stable
	 As described above, chronic stable angina is generally due 
to one or more significant obstructive lesions in coronary 
arteries, obstructive lesions defined as stenosis of $50% 
of the diameter of the left main coronary artery or stenosis 
of $70% of the diameter of a major epicardial vessel. 
Precipitating circumstances remain similar between 
episodes, thresholds may be predicted by patients, and 
relief patterns become known. Since stenoses are fixed, 
the angina is due to demand ischemia.
•	 Decubitus
	 Attacks of decubitus angina occur upon recumbency, 
which raises end-diastolic volume, myocardial wall ten-
sion, and hence oxygen demand.
•	 Nocturnal
	 Anginal discomfort awakens the patient, generally due 
to respiratory pattern changes, episodic tachycardia, 
hypoxia due to respiratory changes, or recumbency.
•	 Refractory
	 Stable chronic angina is termed refractory when it is not 
controllable by a combination of maximal anti-anginal 
medication, angioplasty or coronary artery bypass sur-
gery, or in whom the risks are unjustified.
•	 Unstable (also called crescendo or rest)
	 Unstable angina (UA), is
○	 of recent onset, and/or
○	 discomfort is severe, and/or
○	   occurs at rest or after minimal exertion lasting over 
10 min, and/or
○	   angina with a crescendo pattern – more frequent, 
more severe, of greater duration, or less responsive 
to nitroglycerin.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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UA is an acute coronary syndrome (ACS), and when 
myocardial necrosis becomes evident from elevations in 
  biomarkers, such as troponin I and troponin T,20 the appli-
cable clinical term becomes non-ST-elevation myocardial 
  infarction, or NSTEMI, in the absence of ST-segment 
changes. The European Society of Cardiology defines ACS 
as acute chest pain (ie, chest pain at rest . 20 min within 
the prior 48 hours) together with electrocardiographic 
(ECG), changes suggesting myocardial ischemia and/or 
elevation of cardiac markers.21 About 1.35 million patients 
are admitted to US hospitals annually with the diagnosis 
of unstable angina-NSTEMI. From 38%–47% of patients 
with ACS have ST-segment elevations on the ECG, known 
by the acronym STEMI.
•	 Microvascular (also called Syndrome X)
	 More common in women, angina-like pain, normal 
  coronary angiograms, and positive exercise tests, some-
times with perfusion defects, are a basic diagnostic triad 
in microvascular angina.22 Response to nitrates and other 
anti-ischemic agents is less reliable, and hormonal abnor-
malities, changes in pain perception with exaggerated 
sensitivity, insulin resistance, and psychological overlays 
may be modifying factors. Endothelial dysfunction is one 
pathophysiological suspect,23 but release of vasoactive sub-
stances, autonomic dysfunction, vascular smooth muscle 
dysfunction and loss of estrogen may all contribute. Chest 
pain may occur under conditions of cardiac stress without 
evidence of ischemia. GERD and esophageal motility 
disorders are common comorbidities. In part, treatment is 
difficult because therapeutic responses are not sustained. 
About 1% of patients die and 0.6% suffer a stroke within 
one year after their first hospital admission.
•	 Vasospastic (also called Prinzmetal’s, or angina 
inversa)24,25
	 Described in 1959, this variant form of angina occurs at 
rest, often at night, or with exertion, is caused by focal 
vasospasm of an epicardial coronary artery, and is not due 
to obstructive atherosclerotic lesions. Prinzmetal’s angina 
is known for transient elevation, rather than depression, 
in ST-segments on the electrocardiogram, although 
either may occur. However, most acute patients with 
coronary vasopasm do not have ST-segment elevations, 
which are identified more often during an attack or upon 
provocative testing. Despite an increase in ventricular 
arrhythmias in some patients, the prognosis is gener-
ally better than those with fixed, significant obstructive 
lesions, although response to treatment may be poor.26 In 
the CASPAR study, every fourth patient with an ACS had 
no culprit lesion at coronary   angiography, and in those 
patients epicardial coronary spasm could be documented 
in 50%.27 Coronary vasospasm is a more common cause 
of chest pain and ACS than formerly believed, and may 
contribute to pathology with or without coexisting 
obstructive plaques, more frequently found in men.28 Over 
the years, vasospasm has been linked to low intracellular 
magnesium levels, hyperinsulinemia, defective focal 
nitric oxide production, and use of tobacco or cocaine.
•	 Atypical angina
	 Patients with nonclassical symptoms and signs, such 
as absence of substernal location and character, exer-
tional trigger, or typical relief with rest or nitroglycerin, 
are grouped under the term atypical angina. Atypical 
  presentations are more frequent in women and diabetics, 
displaying variable pain intensity or thresholds, timing, 
and characteristics. Palpitations, sharp lancinating or back 
pain are confounding complaints. The more atypical the 
presentation, results of testing, and responses to provoca-
tion or therapy, the greater the probability of misdiagnosis 
and a poor outcome (see below).
•	 Silent ischemia and anginal equivalents
	 In some patients, particularly diabetics and the elderly,29 
myocardial ischemia may cause symptoms other than 
precordial discomfort. These may include dyspnea, dia-
phoresis, nausea and emesis, fatigue, weakness, altered 
sensorium, light headedness, and fainting. In the absence 
of chest pressure, heaviness, pain or sensorial cognition, 
ischemia is also called silent. Altered pain perception 
and presence of autonomic neuropathy may modulate 
symptom expression. Patients with silent ischemia are less 
likely to be diagnosed correctly and receive appropriate 
attention and treatment, resulting in poorer outcomes. 
In fact, even if there are clear objective findings, such as 
subsequent ST-segment elevation, the absence of chest 
pain during the initial presentation still decreases utili-
zation of both fibrinolysis and percutaneous coronary 
intervention (PCI) later on in such patients’ treatment.30
Diagnosis
Although about 25% of people experience chest pain,31 77% 
of them do not seek medical care despite widespread public 
educational efforts.30 The number of patients presenting 
with chest pain eventually found to have CAD ranges from 
11 to 39%,23 but reports trend closer to 12%.23 Of those 
seen in emergency rooms, about 45%–50% will have a 
cardiac etiology,30,32 with the remaining 50%–55% diagnosed 
with   noncardiac chest pain.31 In primary care practices, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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however, the most common conditions encountered are 
gastroesophageal reflux disease (GERD), musculoskeletal 
pathology, other gastrointestinal conditions, panic disorder, 
pulmonary disease, and stable chronic angina.33,34 Ischemic 
pain is often neglected by patients who mistakenly attribute 
the pain to an episode of indigestion or gas. Characteristically 
this history is elicited retrospectively after it is clear the 
patient has ischemic heart disease.
Questions to ask about chest pain include:35
1.  Background, character, and development of the symptoms.   
For instance, whether pain occurred during effort, an 
acute febrile illness, after trauma.
2.  Area involved, with radiation, if any. 
  For instance, requesting that the patient point to the area 
of pain with a finger may help with focus and elicit a 
response of a clenched fist.
3.  Triggers that initiate the pain.
  For instance, whether pain occurred during effort, emo-
tional stress, sports events on TV , position, eating, etc. The 
threshold of pain may be lower after smoking, eating, or 
cold weather.
4.  Frequency, progression, and duration of the pain.
5.  Factors that relieve the pain.
  For instance, variation of pain with rest, maneuvers, posi-
tion, eating, eructation, antacids, proton pump inhibitors, 
nitroglycerin.
The precipitating factors, characteristics, and natural 
course of angina, along with antecedent history, are typically 
of greater value in evaluation than the physical   examination, 
which is normal in most patients. Discomfort is usually 
described as heaviness, tightness, crushing, squeezing or 
pressure in the precordial, substernal or even epigastric 
area, much more common than peripheral radiation, with 
or without numbness. It is said that radiation to the arms, 
diaphoresis and hypotension suggests myocardial infarction. 
Angina does not vary with change in position, the respiratory 
cycle or cough. Angina reported postprandially is not usually 
of differential diagnostic value. Angina or any equivalent, 
including absence of pain during silent ischemia, may be 
accompanied by dyspnea, nausea, diaphoresis, weakness/
fatigue and apprehension. Therefore, any patient of appro-
priate age with naked, unexplained weakness, dyspnea, or 
nausea, particularly precipitated by activity, sex, or emotion, 
should be investigated for ischemic heart disease along with 
other usual possible etiologies.
Angina must be differentiated from other causes of chest 
pain, the most common summarized in Table 1.
Production and significance of pain
Myocardial ischemia stimulates cardiac sensory receptors 
to initiate a sympathoexcitatory reflex. Bradykinin, protons, 
and other substances released during ischemia activate the 
vallinoid receptor 1 (VR-1) on capsaicin-sensitive cardiac 
sensory nerves (unmyelinated [type C] or thinly myelinated 
[A-δ] fibers).37 The VR-1 receptor acts as a transducer respon-
sible for sensing tissue ischemia, and through sympathetic 
activation, leads to the sympathoexcitatory reflex and the 
pain of angina.38
Table 1 Some noncoronary causes of chest pain
System Diagnoses
Gastrointestinal Peptic ulcer, gastritis, GeRD, cholecystitis, cholelithiasis, choledocholithiasis, esophageal spasm,  
esophagitis, esophageal perforation, pancreatic diseases, some causes of “acute abdomen” such as  
perforations, volvulus, mesenteric adenitis, etc. GeRD accounts for up to 60% of noncardiac cases.36 
Musculoskeletal Chest wall trauma/rib fracture, costochondritis, muscle/ligament/tendon strains, myositis, chronic 
overuse injuries, sternoclavicular arthritis
Pulmonary Pulmonary embolism, severe pulmonary hypertension, pleuritis, pneumonia, pneumothorax, 
bronchiectasis
Nervous Cervical radiculopathy, peripheral neuropathy, brachial plexus impingement, brachial neuritis
Psychiatric Generalized anxiety disorder, panic disorder, hyperventilation, depression, somatoform disorders, 
fixed delusions in thought disorders
Other cardiovascular Pericarditis, acute aortic dissection, aortic stenosis, mitral valve prolapse, idiopathic hypertrophic 
subaortic stenosis (iHSS), cardiac contusion, acute stress cardiomyopathy (Takotsubo’s disease), 
uncontrolled hypertension, coronary anomalies, Kawasaki disease (mucocutaneous lymph node 
syndrome), polyarteritis nodosa, Takayasu arteritis (aortic arch syndrome)
infectious Herpes zoster prior to rash, acute lymphadenopathy, Pott’s disease (tuberculous spondylitis)
Metabolic Hyperviscosity syndrome, acute thyrotoxicosis
Related processes that modulate  
oxygen supply and demand
Angina may be intensified or caused by hypotension, hypoxia, anemia, bradycardia,  
fever, thyrotoxicosis, high output states, such as A-V shunts, systemic and inflammatory  
diseases, especially sepsis, an example of demand ischemia. A hemoglobinopathy  
or carbon monoxide poisoning may interfere with oxygen delivery.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Simultaneously, cardiac sensory nerves also release 
neuropeptides, among them calcitonin gene-related peptide, 
substance P (SP), and neurokinin A, believed to modulate 
myocardial ischemia/reperfusion injury.39 By dilating the 
coronary arteries and through their negative inotropic and 
chronotropic actions, they could reduce negative ischemic 
effects, in part mediated by raised amounts of nitric oxide 
produced by secondary actions of SP.40 Considerable data 
now support an increasingly popular view that VR-1   receptors 
protect the heart during ischemia.41,42 Cardiac afferents from 
the first four thoracic spinal neurons, after interacting with 
other nerves and signals from descending supraspinal loca-
tions, ascend along spinothalamic afferents to the thalamus 
on their way to the cerebral cortex. Anxiety and/or stress, 
frequently associated with CAD, upregulate glucocorticoid 
release and increase sensitization to cardiac nociceptive 
stimuli by modulating upper thoracic neuronal activity.43 
Awareness of the pain may be variable, in part due to an 
interpretive component in the cortex.
It is possible that diabetics have more severe ischemia 
related to neuropathy because their VR1 sensitivity and SP 
production are impaired. Preclinical studies also suggest that 
a reduction in nerve growth factor in diabetics may account 
for failure to experience pain.44 Some evidence exists that 
central processing of afferent pain signals from the heart 
mediates lack of pain in patients with silent ischemia. Pain 
messages are, however, physically received by the brain in 
these patients.
In the light of this new information, angina appears to 
serve as a warning to the patient to stop activity that may 
further ischemic damage and obtain medical care, but simul-
taneously initiates some degree of myocardial protection.
Silent ischemia
Silent ischemia is angina without pain, a unique clinical 
challenge.
While angina is considered a common diagnosis in clini-
cal practice, it is highly likely that prevalence rates remain 
underestimated. Asymptomatic and hence undiagnosed 
myocardial infarction accounted for 33% of transmural 
(Q-wave) myocardial infarctions identified by serial electro-
cardiographic changes and 22% of all nonfatal infarctions 
in the Honolulu Heart Program.45 Recently, using a delayed 
enhancement cardiac MRI (DE-CMR), which identified 
both Q-wave and non-Q-wave myocardial infarctions, a 
study was conducted in 502 subjects with extracardiac 
atherosclerotic disease or advanced risk factors for CAD but 
without symptoms.18 An unrecognized myocardial infarction 
was identified in 13.1% of men and 3.7% of women. There 
was also a suggestion that silent events were associated with 
a poorer prognosis. In the elderly, from 21% to 68% of all 
myocardial infarctions are asymptomatic or unrecognized as 
determined by electrocardiography.18,46,47 In high risk patients 
evaluated with dual-isotope myocardial perfusion SPECT, 
silent myocardial infarction is also common.48
Additionally, silent ischemia is surprisingly frequent 
during continuous electrocardiography, exercise testing, or 
stress echocardiography in high risk patients in a variety 
of clinical situations. Up to 75% of ischemic (ST-segment 
depression $1 mm for $1 min) episodes may occur without 
pain.49 When clinical symptoms of stable angina are thought 
to be controlled, at least 40% of those patients continue to 
show ischemia on monitoring.50 The longer patients continue 
to be monitored, the greater the number of ischemic episodes 
that are detected.51
All things considered, it is becoming evident that most 
ischemic cardiac events are asymptomatic and unrecognized, 
even in patients with typical stable angina who consider 
themselves extremely aware. From 10%–20% of diabet-
ics have silent ischemia and the burden is rising. From the 
significant number of silent myocardial infarctions found on 
electrocardiography and MRI, and asymptomatic ischemic 
episodes during exercise provocation or ambulatory ST- 
segment monitoring, a great number of would-be anginal 
attacks also go unrecognized, undiagnosed, and undertreated. 
Hence the clinical reporting of anginal episodes is quite 
insensitive. Since continuous ECG monitoring is also under-
utilized, the clinical implications are immense.
Patients with silent ischemia have a poorer prognosis 
than those with classical symptoms and may require 
more aggressive therapy.49,52,53 Just one or a few episodes 
of ST-segment depression on 24 hour continuous monitoring 
is associated with a 7.43 rise in risk of AMI or death at 30 days 
in patients with unstable angina.52,54 Silent ischemia remains 
a formidable unsolved clinical problem in all its guises,55–58 
not only with respect to the absence of anginal pain. In 
medicine, random, instant, “snap-shot”, or “ice-pick” samples 
of elements of disease, even as deceptively simple as blood 
pressure or serum glucose measurements, may be disastrously 
misleading when compared to continuous recordings.
Classification and grading
Symptom intensity does not necessarily reflect severity or 
extent of coronary obstruction, but assessment is helpful 
and included in current guidelines.59 Angina is classified 
with respect to functional capacity by the New York Heart Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
640
Kones
  Association functional classification, and according to 
  severity by the Canadian Cardiovascular Society (Table 2).
The Canadian Cardiovascular Society classes correspond 
to the exercise tolerances, shown in Table 3, in metabolic 
equivalent units, MET:62,63
MET =   metabolic equivalent of a task, relative to the 
nominal resting metabolic rate
	  = 3.5 mL O2 (kg−1min−1)
Pathophysiology
Myocardial energy (oxygen) balance
For over 40 years, it has been recognized that myocardial isch-
emia results from an imbalance between myocardial energy 
supply, from insufficient sources of oxygen and substrate 
(glucose, free fatty acids), and myocardial oxygen demand.64–67 
Usually this is simply referred to as an imbalance between 
myocardial oxygen supply and demand, but it should be clear 
that substrate supply, utilization, and enzymatic activities, along 
with other variables involved in intermediary metabolism and 
mitochondrial function, play a major role in the pathogenesis 
of myocardial ischemia in angina, acute coronary syndromes, 
and during reperfusion ischemic injury (Figure 1).
The production of useable energy in the form of ATP 
is determined by the degree of oxidative phosphorylation 
(including nutrient supply) and oxygen availability; hence, 
the two are inexorably intertwined. Major determinants of 
myocardial oxygen demand are heart rate, blood pressure, 
and myocardial wall tension, in turn influenced by preload, 
afterload, and contractility. Since myocardial oxygen extrac-
tion from coronary arterial blood at rest is normally high, 
about 75% of arterial oxygen content,68 adjustments in oxy-
gen extraction cannot correct an imbalance. Physiological 
increases in myocardial oxygen needs are normally provided 
by rises in coronary blood flow.
Coronary autoregulation
Ability of coronary arteries to increase flow to meet myo-
cardial metabolic demand, called coronary flow reserve, is 
about 4–6 times the resting value at maximum dilatation of 
the coronary arteries,68,69 which can be somewhat expanded 
pharmacologically. Coronary autoregulation is a complex 
phenomenon with many regulating variables.70 Superimposed 
upon the hierarchy are the influences of disease upon each 
variable – atherosclerosis, ischemia, hypertrophy, alterations 
in autonomic nerve function, endothelial function, electro-
physiology, etc.71 Up to 95% of the resistance in coronary 
vessels arises within small intramural vessels, about 10 nm 
to 140 nm in diameter, which are not visualized during coro-
nary angiography or multislice CT angiography, a procedure 
identifying epicardial arteries with diameters from a few 
mm to about 500 µm (arterioles with a   diameter ,100 µm 
and prearterioles with diameters from ∼500 µm to ∼100 µm 
Table 2 Classifications of functional capacity and severity in angina patients
Class (limitation  
of normal activity)
New York Heart Association Functional 
Classification (NYHA)60
Canadian Cardiovascular Society Severity 
Classification (CCS)61
Class i (Minimal/No limitation) Heart disease exists with no symptoms or 
limitation of physical activity. Ordinary physical 
activity does not cause angina, fatigue, 
palpitation, or dyspnea that limit activity.
Ordinary physical activity (such as walking or 
climbing stairs) does not cause angina. Angina 
may occur with strenuous rapid or prolonged 
exertion at work or recreation.
Class ii (Mild/Slight limitation) There is slight limitation of physical activity. 
Comfortable at rest, but ordinary physical activity 
results in angina, fatigue, palpitation, or dyspnea.
Angina may occur with 
• walking or climbing stairs rapidly; 
• walking uphill; 
•   walking or stair climbing after meals or in the 
cold in the wind or under emotional stress;
•   walking more than 2 blocks on the level at a 
normal pace and in normal conditions
•   climbing more than 1 flight of ordinary stairs 
at a normal pace and in normal conditions
Class iii (Severe/Marked limitation) Patients have marked limitation of physical activity. 
Comfortable at rest, but less than ordinary activity,  
such as walking 20–100 m, causes fatigue,  
palpitation, or dyspnea.
Angina may occur after 
• walking 1–2 blocks on the level 
•   climbing 1 flight of stairs in normal conditions 
at a normal pace
Class iV (extreme limitation) Severe limitation; unable to carry out any physical 
activity without discomfort. Angina and/or symptoms  
of cardiac insufficiency may be present at rest.  
if any physical activity is undertaken, discomfort  
is increased. Usually self-confined to bed or a chair.
Angina may be present at rest. inability to 
perform any physical activity without 
discomfort.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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are below the resolutions of angiography and are not 
visualized).
About 5% of the resistance that determines coronary 
blood flow arises within the conductive epicardial coronary 
arteries. Resolution limitations of coronary angiography pre-
clude assessment of pathology in the important   microvascular 
bed, where alterations are common in ischemic heart 
Table 3 exercise capability corresponding to Canadian Cardio­
vascular Society Functional Classifications
Functional 
class
Exercise  
tolerance (METs)
Approximate activity level
i 7–8 Strenuous: 
  Jogging, 1 mile in 12 min
ii 5–6 Vigorous: 
    Brisk walking, 1 mile in 15 min;
  Slow jogging, 1 mile in 13 min
iii 3–4 Moderately vigorous: 
    walking at a brisk pace,  
1 mile in 20 min
iV 1–2 extremely light activity: 
    Minimal ADL, walk at  
1 mile per hr
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Figure 1 Global relationships and positive feedback loops relating to the inequality of myocardial oxygen supply and demand.
Many of the global relationships and positive feedback loops relating to the inequality of myocardial oxygen supply and demand have not changed in many years, although molecular, 
electrophysiological, conceptual, and technological advances have been considerable. Myocardial energy imbalance is central to all ischemic syndromes: angina, myocardial 
infarction, and cardiogenic shock. The variables determining myocardial oxygen supply (right) are altered by negative feedback loops from complications of poor left ventricular 
function (center, lower cycle). Those factors affecting myocardial oxygen demand (left, as heart rate, afterload, preload, contractility) are altered by positive feedback loops from 
those events perpetuating systemic features. An increase in left ventricular end­diastolic pressure (LV­eDP) or volume (LV­eDV) increases preload according to LaPlace’s Law. Both 
the negative feedback on oxygen supply and the positive feedback on oxygen demand tend to further the inequality between the two and may jeopardize poorly perfused myocardial 
tissue. when ischemia progresses beyond the reversible stage of angina and myocardial necrosis follows, well­known hemodynamic, metabolic and mechanical sequellae may occur. 
Reproduced with permission from Kones, 1973.65
disease, hypertension, diabetes, and autoimmune vascular 
pathology. The microvascular bed may respond to therapies 
differently than epicardial vessels.72 In considering that 
about 30% of patients referred for coronary angiography 
have normal or nonactionable reports, it is understood that 
the vast microvascular bed has not been evaluated. When 
angiography is used to assess accuracy of stress perfusion or 
echocardiographic testing, these limitations are pertinent.73 
Measurement of blood flow using positron emission tomog-
raphy is a useful tool in assessing coronary dynamics, 
especially in combination with other imaging techniques.74 
A more aggressive stance in treating ischemic heart disease 
(IHD) requires an improved, detailed understanding of the 
microvasculature.
In patients with stable angina, a fixed reduction in 
the diameter of coronary arteries by at least 70% dictates 
an obligatory reduction in coronary blood flow in one or 
more coronary arteries. The inability to increase oxygen 
extraction or coronary blood flow, together with elevated 
myocardial energy demand, leads to anginal pain, variably 
accompanied by panoply of metabolic, electrophysiologic, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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and   hemodynamic consequences. Most events that trigger 
angina do so by changing myocardial oxygen demand, viz, 
increases in heart rate (jogging, sexual activity), afterload 
(doing a difficult bench press, not taking blood pressure 
medication), preload (consumption of a sodium-loaded pizza 
by a patient with heart failure and CAD), or contractility (in 
part, watching an exciting sports event or explosive anger 
with subsequent catecholamine discharge). Similarly, the 
beneficial effects of most maneuvers that relieve angina may 
be explained through corrective alterations in the determi-
nants of myocardial oxygen supply and demand.
Endothelial dysfunction within atherosclerotic coronary 
arteries is abnormal, and nitric oxide production may be 
reduced and contribute to myocardial oxygen imbalance.
Clinical pathology
Over the past few years, an important distinction between 
the pathology of acute and chronic coronary syndromes 
has been made. In the patient with chronic coronary artery 
disease and fixed obstructive coronary lesions, sudden 
increases in myocardial oxygen demand, usually due to 
effort, in face of the inability to raise myocardial blood 
flow and oxygen supply, result in a transient myocardial 
energy imbalance and demand ischemia. The fixed areas of 
stenosis responsible are those which are likely to be seen on 
coronary angiography. In contrast, the majority of patients 
with an acute coronary   syndrome suffers sudden reduction of 
coronary blood flow due to a discrete plaque event: rupture, 
erosion, or hemorrhage in a vulnerable plaque.75 A physical 
disruption in the plaque exposes platelets to collagen, 
initiating adhesion and aggregation, while tissue factor in 
plaque induces coagulation, and thrombus formation ensues 
with variable degrees of arterial obstruction. Vulnerable 
plaques may not be visualized during coronary angiography. 
  Subclinical microembolism, smooth muscle hyperreactivity, 
and endothelial dysfunction may also contribute to progres-
sion of the syndrome. Many fatal   intraarterial occlusions 
arising from plaque rupture do not occur at highly stenotic 
areas in coronary arteries. After myocardial infarction, since 
prognosis is significantly determined by the amount of muscle 
destroyed during ischemia/reperfusion,66,76 ensuring vessel 
patency and limiting injury to preserve myocardium are the 
overriding concerns.
Not every plaque disruption causes a total arterial 
occlusion or even clinical manifestations. Rather, the 
process is ongoing, involving inflammation, thrombosis, 
reabsorption of thrombus, fibrosis and remodeling of 
the plaque over time that determines whether coronary 
blood flow will continue unimpeded. The processes of 
thrombus dissolution,   organization, plaque cell and lipid 
accumulation and synthesis of extracellular matrix cannot 
be predicted. An inflamed plaque with intense oxidative 
stress may continue to enlarge its lipid pool and accumulate 
inflammatory cells that produce excessive amounts of 
protease,77 resulting in a thin, friable, fibrous cap. The 
metalloproteinases in particular, expressed by macrophages 
and smooth muscle cells within plaques, degrade matrix 
collagen and elastin. In contrast, the plaque may stabilize 
and remodel inward during healing, decreasing its lipid 
pool, accumulate extracellular matrix, thicken its fibrous 
cap, and maintain a variably patent lumen. Alternatively, 
vulnerable plaques may rupture, heal, become relatively 
stable, but then shrink (negative remodeling) causing 
stenosis and low blood flow requiring revascularization.78 
Lesion evolution and progression include organizing 
thrombi from otherwise lethal ruptures that may remodel 
and heal well. Outward expansion of evolving plaque (posi-
tive remodeling) may limit luminal encroachment, but is 
paradoxically associated with vulnerable unstable lesions 
containing large lipid cores rich in macrophages. The lesion 
considered most vulnerable is the thin-cap fibroatheroma 
with a large necrotic lipid core (.34% of plaque area) and 
a thin fibrous cap (thickness ,65 µm). However, plaque 
remodeling is heterogeneous, involving intra-plaque 
hemorrhage and erosions of fibrous plaques. Recent infor-
mation suggests that erosions rather than ruptures and may 
occur in the young, particularly women, who succumb 
to sudden coronary death.79 Erosions may be even less 
identifiable on stress testing and coronary angiography, 
and may result from repeated coronary vasospasm. Distal 
microembolization as a later complication of thrombosis 
is also of interest.80
Differences in plaque from patients with chronic stable 
angina and acute myocardial infarction have been reported 
using optical coherence tomography (OCT) imaging to assess 
plaque vulnerability.81 Acute myocardial infarction (AMI) 
survivors who were undergoing percutaneous interventions 
and those with stable lesions in multiple vessels had OCT 
images performed of infarct-related lesions or lesions 
slated for revascularization, as well as noninfarct-related 
and nontarget lesions. OCT images found intracoronary 
thrombus in all patients with AMI, and none in stable 
angina patients. Plaque rupture was identified in 77% of 
AMI patients, but only in 7% of stable angina patients. 
Thin-cap fibroatheroma were much more common in the 
AMI patients, not only in infarct-related culprit lesions, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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but in others as well. The authors concluded that thin caps 
were part of a diffuse   inflammatory process in patients with 
acute events. Rates of plaque rupture in noninfarct-related 
lesions in AMI patients and nontarget lesions in stable angina 
patients were similar.
The myocardial oxygen imbalance of chronic stable 
angina is characteristically reversible short term and unas-
sociated with myocardial necrosis. In contrast, the extent 
of the imbalance in acute coronary syndromes generally 
produces muscle cell death. To help begin decide which it 
is, even imperfectly, the American College of Cardiology/
American Heart Association (ACC/AHA) guidelines advise 
a resting electrocardiogram (ECG) be done in all patients 
with symptoms of angina.59 The ECG will be either normal 
or nondiagnostic about half the time, and false positive and 
negative findings in patients with angina abound. In half of 
such patients with a normal resting ECG, one recorded during 
chest pain may reveal a significant change. Even advanced 
CAD may be present with a normal ECG.
Interventions that reduce cardiometabolic risk, to be 
discussed in Part II of this review, may promote plaque 
stabilization by lowering inflammation, oxidation, and sup-
press the thrombotic cascade. Many nonpharmacological 
and some pharmacological treatments, especially statins, 
are pleiotropic in the sense that they not only improve lipid 
profiles, but also act in other ways to impede inflammation 
and destructive events.82
Pretest stratification  
and probability of ischemia
The three elements of typical angina include
a.  substernal discomfort with location, characteristics and 
duration as discussed above,
b.  provocation by effort or emotional stress, and
c.  relief by rest or nitroglycerin.
The likelihood that a patient will have a firm diagnosis of 
CAD or obstructive lesions on coronary angiography from 
the clinical description of chest pain varies according to 
age, sex, and number of these three typical elements in the 
presentation. For instance, at age 45, if the history contained 
all three criteria, 87% of men would have CAD, but only 55% 
of women.59,83 If the history contained two elements, ie,  were 
atypical, these would be 51% and 22%, respectively. If the 
chest discomfort described had none of the three elements, 
ie, were noncardiac, 13% of men and 3% of women would 
have CAD.
A few patients with obstructive CAD in fact would be 
missed clinically. Women have significantly less obstructive 
CAD than men at the same age, and even when the history is 
negative for ischemia, there will be some patients who will 
have CAD in all groups.
At age 65, if all three elements of typical angina are 
  present, 94% of men and 86% of women will have CAD. If 
no elements are present, ie, the chest pain is noncardiac, 27% 
of men and 14% of women will have CAD. As age increases, 
the correlation between the number of typical elements and 
diagnosis rises. As women age, especially beyond menopause, 
a greater proportion of those presenting for care will have 
demonstrable obstructive lesions than younger women.
The probability of ischemic  
heart disease
An assessment of the pretest probability of ischemic heart dis-
ease (IHD) is required for a decision about further testing.
If pain lasts . 20 min at rest, reproduces pain previously 
documented as angina, and/or there is associated transient 
mitral regurgitation, diaphoresis, hypotension, or pulmonary 
rales, the probability of ischemia is high.
If there is new ST-segment deviation $ 0.5 mm, T-wave 
inversion $ 2 mm, new left bundle branch block or a serious 
ventricular arrhythmia, an ischemic origin is likely.
Elevations in cardiac biomarkers indicate myocardial 
necrosis and reclassify the patient by definition.
Features suggesting an intermediate probability of 
ischemic origin include absence of the above, pain . 20 min 
but abated with rest or nitroglycerin, male gender, age over 
70 years, presence of diabetes, extracardiac vascular disease, 
fixed Q waves, and resting ST depression # 1 mm in multiple 
lead groups. While the presence of left ventricular hyper-
trophy somewhat raises probability of associated ischemia, 
it is not diagnostic. Similarly, while the finding of several 
traditional risk factors is of interest and to be weighed, severe 
CAD may be present without them.
Features arguing for a low likelihood of an ischemic 
origin exist if
a.  none of the findings above are present,
b.  the patient has used cocaine prior to the episode or there 
is a documented history of recurrent panic attacks and/
or hyperventilation with similar pain,
c.  there is chest wall tenderness, and/or
d.  the ECG is normal, shows T-wave flattening, or T-wave 
inversions in leads with dominant R waves.84
None of these features are diagnostic.
Placing great predictive value upon one feature of the 
presentation may lead to a diagnostic error, for without a 
coronary angiogram, the possibility of obstructive CAD Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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always remains open. New angina may also occur in patients 
who have histories of common diseases well known to mimic 
angina, such as GERD, esophageal spasm, peptic ulcer, and 
cholecystitis, all of which may be indistinguishable clinically. 
Although the differential diagnosis is familiar to physicians, 
errors remain a frequent subject of lawsuits. Up to 12% of 
patients who are discharged from emergency departments 
(EDs) with a noncardiac diagnosis have had or will sustain 
an AMI.
New imaging techniques, especially in EDs, and biomark-
ers currently available for both AMI and rule out diagnoses 
now offer greater assistance in improving accuracy of diag-
nosis and treatment.85,86 For instance, the use of new high 
sensitivity troponin assays, hs-cTnT, properly used, provide 
sooner exclusion and potentially improved identification of 
myocardial necrosis.87–91 In addition, the increasing use of 
chest pain units in hospitals may improve patient outcomes 
and possibly reduce inappropriate hospital admissions.92–94
By following applicable guidelines and pursuing objec-
tive data to confirm clinical impressions, the careful physician 
will avoid many of the common pitfalls in clinical decision 
making leading to misdiagnosis and/or mistreatment.
Diagnostic studies
The choice of how to proceed depends upon the individual 
patient, and also reflects the two objectives of noninvasive 
testing. For those with new onset chest pain, the need for 
diagnosis predominates, and the question to be answered is 
whether or not ischemia due to obstructive atherosclerotic 
lesions is present. In established patients, the dominant issue 
is risk stratification and whether coronary angiography is 
needed for further management.
Exercise ECG testing
In general, most patients – all but those with extremely low 
probabilities of an ischemic origin of their chest pain – should 
receive graded exercise testing, particularly if the resting 
ECG is normal. The Bruce protocol and Duke Treadmill 
Score are commonly used. Patients must be able to exercise 
adequately, and be free of confounding features precluding 
interpretation on the resting ECG.95 The test may reveal typi-
cal changes of ischemia on the ECG in association with chest 
pain, which clarifies the diagnosis, and the patient’s exercise 
capacity may provide further direction in treatment. Together 
with the Duke Treadmill score, exercise testing gives pre-
dictive information concerning survival. Exercise tests are 
most valuable when there is an intermediate probability of 
CAD, according to Bayesian theory, and are recognized 
by the ACC/AHA Task Force on practice guidelines as an 
important asset in such patients for clinical decision making.59 
However, when the probability of CAD is high, the exercise 
test may be indicated for risk stratification, prognosis and 
clinical direction.83
Exercise tests are not indicated in patients with   preexcitation 
syndromes, those that are being paced, have complete left 
bundle branch block (LBBB), over 1 mm of ST segment 
depression at rest, a myocardial infarction within the pre-
vious two days, unstable angina, pericarditis, active ECG 
changes, severe aortic stenosis or lung disease, ongoing poorly 
  controlled arrhythmias, uncontrolled hypertension, active cere-
bral ischemia or embolic phenomena, advanced lung   disease, 
heart failure, aortic dissection, myocarditis/endocarditis, or 
other major unresolved problems. Generally β-blockers, nodal 
blockers, and nitrates are discontinued about two days before 
testing and digoxin about one week beforehand. The test 
should be aborted if there is chest pain, severe dyspnea, diz-
ziness or near syncope, fatigue, ST elevation $ 1 mm without 
diagnostic Q waves, ST depression $ 2 mm, fall in systolic 
BP . 10 mmHg, or a ventricular arrhythmia.
An exercise test is positive for ischemia if any of the 
following occur:
•	 New flat or downsloping ST-segment depression $ 1 mV 
below the baseline, at least 0.06–0.08 sec after the QRS 
complex J-point in multiple leads, the most reliable indi-
cator of ischemia.95 If it appears during a low workload, 
prognosis may be worse.
•	 New ST-segment depression at the start of exercise 
(within 3 min);
•	 ST-segment depression persists beyond 6 min of the 
recovery phase;
•	 Fall in systolic blood pressure during exercise (normally 
this rises because of increased stroke volume);
•	 Development of acute heart failure or sustained ven-
tricular arrhythmias. Significant ventricular ectopy dur-
ing recovery has greater significance than ectopy during 
exercise.
•	 Development of characteristic chest pain during 
exercise;
•	 Inability to exercise more than 2 min on a cardiac 
basis.
The exercise test is imperfect, with false-negative and 
false-positive results one-third of the time, but is useful, 
inexpensive, widely available, simple and practical. For 
instance, if the test is positive in a male with a history of 
classical angina, he develops chest pain during the test, 
and is over 50 years of age, there is a 98% probability Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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he has advanced CAD. On the other hand, with limited 
sensitivity, a negative test strongly argues against more 
ominous forms of CAD such as three-vessel or left ante-
rior descending coronary obstruction, but certainly does 
not exclude CAD. The sensitivity and specificity is 68% 
and 77% respectively.96,97 Specificity is reduced in middle-
aged females, with a false positive rate of 17% compared 
to 11% in males.98
Some investigators believe the overall accuracy of ST 
segment depression on exercise ECG testing is only about 
65%.99,100 For this reason an additional scoring system using 
three independent variables: exercise time; ST segment 
deviation; and angina index has been used extensively, and 
was incorporated into the ACC/AHA Guidelines for exercise 
testing.96 The Duke Treadmill Score (DTS) quantitates risk, 
assists with prognosis, and is calculated as follows101
DTS = Exercise time (min) −
  [5 × ST segment deviation (mm)] −
  [4 × angina index]
where the angina index is
0 if no angina occurs anytime,
2 if angina is the reason for stopping the exercise test, and
1 if angina occurs during the test or during the recovery 
period.
If DTS is $5, risk is low, the associated 4 year survival 
is 99%, and such patients should be managed medically. If 
DTS is ,(−10), risk is high, the 4 year survival is 79% with 
an average mortality of 5%, and such patients should be 
referred for coronary angiography. Approximately 4% of 
patients have high risk DTS, and about two-thirds of patients 
have low risk DTS (Table 4).101
Patients with overtly positive exercise tests should 
undergo cardiac catheterization with revascularization in 
mind. Further indications, precautions, contraindications, 
caveats, interpretation criteria, and details of exercise testing 
are given in the full ACC/AHA guidelines.96,102
Stress imaging
Stress imaging includes myocardial perfusion, stress echocar-
diography, and other techniques.
Compared to exercise electrocardiography, perfusion 
imaging with 201thallium or 99mtechnetium-sestamibi raises 
sensitivity, but prognostic value is less established.102 
  Perfusion imaging is particularly useful when the resting 
ECG is abnormal, in women because of false positives 
on stress ECG,103 and in symptomatic patients who have 
had prior revascularization, reversible areas of ischemia 
may be quantified and localized to specific areas of the 
myocardium.104
99mTechnetium-sestamibi produces better and faster 
images with decreased attenuation, has lower   sensitivity 
for viable myocardium than  201thallium, and is more 
expensive.
Increased lung uptake post testing, left ventricular dila-
tion, and multiple perfusion defects are associated with left 
main coronary or severe multivessel disease and should 
be followed by coronary angiography. Patients with two 
or more perfusion defects and ventricular dysfunction are 
also candidates for angiography. Use of perfusion imaging 
has been found to lower rates of hospital admission by up 
to 52% while evaluating acute chest pain in the emergency 
department.105
A number of patients who require stress testing are 
unable to exercise, most frequently due to peripheral vascu-
lar disease, a prior stroke, arthritis, lung disease, neurologi-
cal disorders, or simply deconditioning in the elderly. In this 
circumstance pharmacological challenge is performed using 
dipyridamole, adenosine, or dobutamine. Dipyridamole 
and adenosine raise blood flow in healthy coronary arter-
ies, stealing blood from myocardium served by obstructed 
vessels. After administration of either of these two agents 
the perfusion imaging study is performed. Dipyridamole 
may cause bronchospasm and is not used in asthmatics. 
Xanthines may cause false-negative studies. Adenosine 
may produce flushing, dyspnea, chest pain, and bradyar-
rhythmias, and cannot be used in a patient with sick sinus 
syndrome or high grade AV block. Alternatively, a graded 
infusion of dobutamine may be used to raise myocardial 
oxygen demand prior to perfusion imaging, and is useful 
in patients who cannot raise their heart rates adequately 
during exercise.
If the initial evaluation of the patient with angina sug-
gests heart failure, pulmonary hypertension, valve disease 
or hypertrophic cardiomyopathy, echocardiography may 
be considered. In addition, baseline or follow-up measure-
ment of systolic or diastolic function may be of value in 
rehabilitation. Echocardiography may be also used with 
or without exercise or pharmacological stress to reveal 
Table  4  Duke  Treadmill  scores  (DTS),  survival,  and  annual 
mortality
Risk level DTS 4 Year  
survival (%)
Overall  
survival (%)
Annual  
mortality (%)
Low $5 99 62 0.25
Moderate  −10 – +4 95 34 1.25
High ,−10 79 4 5.0Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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segmental wall motion abnormalities associated with isch-
emia. Stress echocardiography is more sensitive than stress 
electrocardiography. Exercise makes normal myocardium 
hyperdynamic, but ischemic walls become hypokinetic or 
akinetic. Accuracy is comparable to perfusion imaging, not as 
widely available, and less expensive. Since it is the only stress 
technique that evaluates ventricular function, valve disease, 
and cardiac dimensions, it has special value in patients with 
aortic stenosis, idiopathic hypertrophic subaortic stenosis, 
or changing murmurs.
Magnetic resonance coronary angiography (MRCA) is 
an exciting and promising addition to cardiac imaging.106–109 
While useful in the emergency department for triage, infor-
mation derived is primarily anatomic rather than functional 
or predictive; present limitations will no doubt be improved 
with further research and development.110 Both MRCA and 
computed tomographic coronary angiography (CTCA) are 
effective as rule-out techniques but remain imperfect. Radia-
tion exposure and need for contrast with CTCA detracts from 
long term interest. An excellent authoritative review of both 
techniques is available,111 and recent criteria for appropriate 
cardiac radionuclide imaging with further details are sum-
marized in a consensus statement.112
Current guidelines clearly indicate that in most patients 
a noninvasive test should be performed prior to coronary 
angiography, but in about 15% of cases, it is not done.
Table 5 has a comparison of sensitivity, specificity, and 
predictive accuracy of noninvasive tests currently used for 
diagnosis and stratification of patients suspected of having 
coronary artery disease.
Risk stratification after  
noninvasive testing
Evidence based guidelines stratify patients into three 
  categories: high, intermediate, and low, for clinical decision 
making and advising patients about their choices.59 Inclusion 
criteria for these categories based on noninvasive testing 
are summarized in Table 6.
Coronary angiography
Coronary angiography remains the gold standard for the 
diagnosis of CAD, and defines the location(s) as well as the 
extent of the disease. As mentioned, it should be performed 
in patients with angina who have a markedly positive stress 
test, but also in those in whom testing strongly suggests left 
main coronary artery or three-vessel disease. Other indications 
include patients who may have a nonatherosclerotic cause of 
ischemia such as a coronary arterial anomaly, those who have 
frequent readmissions for chest pain, who are resistant to medi-
cal therapy (disabling angina despite optimal evidence based 
medical management), who have undergone prior revascular-
ization procedures, those with indeterminate stress tests and 
clinical features of severe CAD, those with heart failure, some 
patients who are unable to proceed with noninvasive evalua-
tion, or whose occupation demands a definitive diagnosis.
Coronary angiography also refines prognosis. In patients 
referred for angiography and subsequently treated medically, 
in those who had three-vessel disease, the 12 year survival 
was 40%; in those with two-vessel disease, it was 59%; in 
patients with one vessel obstructed, 74%; and in patients with 
normal coronary arteries, there was 91% survival over the 
same period.113 Extent and location of obstruction may be 
precisely quantitated; when lesions are proximal, prognosis 
is worse. Simultaneously, left ventricular function, a critical 
determinant of prognosis, may also be accurately character-
ized. Coronary angiography provides precise information 
about two of the four most important predictors of long 
term survival: left ventricular systolic function and extent 
and distribution of obstructions. Unfortunately, however, it 
does not quantify plaque stability and probability of rupture, 
a third determinant of outcome and a topic of great current 
interest. The fourth determinant of risk and prognosis of 
Table 5 Tests used for diagnosis and prognosis in ischemic heart disease*
Test type Sensitivity (%) Specificity (%) Predictive accuracy (%)
exercise eCG 68 77 73
Duke Treadmill score – – 80
201Thallium perfusion scan 85 85 85
99mtechnetium­sestamibi/SPeCT 88 72 80
Adenosine SPeCT 90 82 85
exercise echocardiography 85 81 80
Dobutamine echocardiography 88 84 86
Computed tomography: electron beam  
tomography (eBCT) calcium score
60 70 65
*Data vary according to studies included and characteristics of patient group studied, eg, number of coronary vessels involved, etc.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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patients with ischemic heart disease is general health and 
extra-coronary comorbidity.59
Use of coronary angiography as a screen, especially in 
symptom free patients, has been criticized because of low 
diagnostic yield, with up to 38% of “negative” studies, in view 
of the radiation exposure and potential adverse events.199 
However, a normal result does not imply that a procedure 
is not indicated or is overutilized. When used appropriately 
according to current decision guidelines, both the negative 
as well as the positive information obtained is necessary for 
optimal management. Such discussions about overuse of 
coronary angiography do not apply to the urgent evaluation of 
chest pain, or to patients with known CAD, in whom potential 
benefits clearly outweigh potential procedural risks. The high 
frequency of false negative coronary angiograms in some sub-
sets of patients only underscores the need for improving the 
diagnosis of obstructive CAD, following guidelines, and con-
tinuing the search for additional data and new techniques.
Gender differences in CAD
Gender differences in CAD are now acknowledged and rec-
ognized, but not yet fully characterized or incorporated.
Angina is the most common symptom of IHD in 
women. Age, gender, ethnic, regional and socioeconomic 
differences in patients with chest pain and heart disease, 
spawning inequalities or disparities in care, have long been 
neglected, and remain only partially addressed open issues, 
requiring further research and action.114,115 Etiology, risk 
factors,   pathogenesis, presentation, evaluation, diagnostic 
testing, physicians’ choice of treatment, response to therapy, 
and outcomes are all gender specific.116 Even initiation or 
restarting drugs for secondary prevention lags in women. 
Gender differences in presentation of chest pain and angina 
are important and merit greater awareness among all members 
of cardiac service teams. Moreover, women have a 20 percent 
higher prevalence of stable angina than men.117
The typical triad of angina includes effort induced 
substernal pressure or tightness and relief upon rest or use of 
nitroglycerin. Patients with atypical histories and symptoms, 
especially women,116,118,119 are more likely to be misdiagnosed 
and under treated. Women with acute coronary syndromes 
(ACS) have more dyspnea, indigestion, nausea and vomiting, 
weakness, and back pain than men.120,121 In a recent study, 
a significantly greater number of men presenting with chest 
pain (17%) had a diagnosis of CAD than women (13%), 
and chest pain lasting from 1–12 hours in women was more 
likely to be due to CAD than in men, who reported a shorter 
episode (30–60 min).122 Another series of 112 women and 
144 men admitted for ACS confirmed greater reporting of 
indigestion, palpitations, nausea, numbness of the hands, and 
fatigue in women.123 The vagueness and nonspecific nature of 
these symptoms poses difficulties in clinical   decision   making. 
Table 6 Risk stratification based upon noninvasive testing in patients suspected of having ischemic heart disease
Risk level Annual mortality rate (%) Clinical indicators
High .3 • Severe resting left ventricular dysfunction (LVeF , 35%) 
• High risk Duke treadmill score (DTS = (−11)) 
• Severe exercise left ventricular dysfunction (exercise LVeF , 35%) 
• Large stress induced perfusion defect, particularly if anterior 
• Multiple stress induced perfusion defects of moderate sizes 
• Large, fixed perfusion defect with LV dilation or increased lung uptake (thallium-201) 
•   Stress induced moderate perfusion defect with LV dilation or increased 
lung uptake (thallium­201)
•   echocardiographic wall motion abnormality (involving . 2 segments)  
developing at low dose of dobutamine (= 10 mg/kg/min) or at a low
• Heart rate (,120 beats/min) 
• Stress echocardiographic evidence of extensive ischemia
intermediate 1–3 • Mild/moderate resting left ventricular dysfunction (LVeF = 35%–49%) 
• intermediate risk Duke treadmill score [DTS = (−11) to (,5)] 
•   Moderate stress induced perfusion defect without LV dilation or increased  
lung intake (thallium­201)
•   Limited stress echocardiographic ischemia with a wall motion 
abnormality only at higher doses of dobutamine involving 1–2 segments
Low ,1 Low risk treadmill score (DTS = 5) 
Normal or small myocardial perfusion defect at rest or with stress 
Normal stress echocardiographic wall motion or 
no change of limited resting wall motion abnormalities during stress
Abbreviations: LV, left ventricular; LVeF, left ventricular ejection fraction; DTS, Duke treadmill score.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Ischemic heart disease is a different disease in women and 
is strongly dependent upon stage of life; in young women, 
differences are even greater (Table 7).
Evaluation, appropriateness of treatment, and research 
inequality in women, with respect to atherosclerosis progres-
sion, relief of symptoms and ultimate prognosis, are concerns 
that begin with risk factor differences between genders183 
and persist even beyond percutaneous coronary intervention 
(PCI).184 For instance, a gender delay in emergency medical 
services in Dallas County, Texas was dismissed as minor, 
but women were actually 52% more likely than men to be 
delayed 15 min or more from the time emergency medical 
services teams arrived in response to a call and reaching 
a hospital, potentially involving additional myocardial 
cell death, critical in subsequent complication rates and 
prognosis.161,162 Interestingly, during an evaluation of gender 
differences in the management and prognosis of myocardial 
infarction, women had a higher body mass index and more 
diabetes, renal dysfunction and depression, but less chronic 
lung disease, smoking history, cancer, and fewer prior myo-
cardial infarctions than men.185
Cardiac electrophysiological differences between men and 
women are well known.186 Women have longer QT intervals, 
and estradiol and testosterone are capable of altering portions 
of the cardiac action potential. Estradiol has been linked to 
after-depolarizations and torsades de pointes in laboratory 
animals. Inappropriate sinus tachycardia, more common in 
women, may be related to both autonomic dysregulation of 
the sinus node and/or an immunological disorder of cardiac 
β-adrenergic receptors. Significant gender differences 
in sudden cardiac death have been reported, including 
different responses to therapy. Despite equal benefits derived 
from such devices, utilization of implantable cardioverter 
defibrillators and cardiac resynchronization therapy is lower 
in women.187
Women enjoy premenopausal protection against IHD, 
which may be blunted by diabetes, multiple risk factors, 
and a myocardial infarction. Why women, with a higher 
prevalence of risk factors, clinically more difficult angina, 
fewer obstructive coronary lesions, and milder myocardial 
infarctions have poorer clinical outcomes, most accentuated 
in younger women, remains uncertain.14,188 Another feature 
of the paradox is the higher incidence of heart failure in the 
face of better left ventricular systolic function, as compared 
with men, before PCI. Fundamental biological differences 
between sexes, especially microvascular dysfunction, with 
smooth muscle, endothelial, and autonomic nervous system 
components, appear to contribute to ischemic physiology in 
women (Table 7). However, as attractive as the endothelial 
and microvascular dysfunction hypothesis is, supporting 
data are not yet robust. Failure to follow guidelines equally, 
ie, gender bias in invasive procedures, accounts for only a 
part of the difference.189,190
Perhaps the lack of a single cohesive explanation of dif-
ferences between the pathophysiology of IHD in women and 
men contributes in a small way to gender disparities, since the 
message cannot be underpinned with a large, single arrow. 
Nonetheless, women generally do not receive sufficiently 
intense therapy when treated medically for CAD,189,191 nor 
after AMI,192 with or without obstructive CAD. However, 
women with chronic stable angina and CAD most certainly 
benefit from, and deserve, full medical therapy just as do 
men,193 and the guidelines are clear.
A meta-analysis of randomized trials compared the effects 
of a conservative vs an invasive strategy in women and men 
with acute coronary syndrome without ST-elevation.194 While 
high risk patients of either sex enjoyed a 20% reduction in 
the composite endpoint of death, myocardial infarction, or 
recurrent ACS, an early invasive treatment in women with 
angina/ACS and negative biomarkers was associated with 
a 35% increase in risk of death. Men did not face this risk. 
These data significantly tempered enthusiasm for aggressive 
ACS strategies in low risk women, and ACC/AHA guidelines 
now recommend an invasive strategy in high risk women 
(the same as men), but in low risk women, a conservative 
strategy is advised.195–198
Goals in management  
of the patient with angina
There are generally three inter-related goals in managing 
patients with stable chronic angina:
•	 Limit the number, severity, and sequellae of anginal 
attacks, including psychological consequences, thereby 
increasing quality of life.
•	 Protect against future, potentially more lethal ischemic 
syndromes, such as sudden death, myocardial infarction, 
and cardiogenic shock.
•	 Lower the risk for atherosclerosis progression.
Conclusion
The diagnosis of chronic stable angina is made clinically, and 
is further refined by laboratory data, including electrocar-
diography, exercise testing, imaging, and possibly coronary 
angiography. Coronary artery disease, or ischemic heart 
disease, is the leading cause of death in the United States. 
Angina is one of the syndromes produced by CAD, and chest Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 7 Some observations of interest about angina/ischemic heart disease in women*
Category Finding or observation
etiology: Cellular events  
and the vascular bed
• Myocardial weight, myocyte number and volume better preserved with age
•   incidence of vasculitis, vasospastic disorders, Raynaud’s phenomenon­, and migraine are higher in women.
•   Autoimmune diseases, more frequent in women,124 may be linked to inflammation and/or reactivity.
• increased coronary arterial reactivity is observed in women.125
•   Differences in microvasculature have been attributed to sex hormone/receptor variations generally.
•   There is impairment in coronary flow reserve as judged by intracoronary response to adenosine, attributed to 
microvascular smooth muscle dysfunction.126
• Vasospastic angina is caused by coronary microvascular spasm.127
•   endothelial involvement128 and autonomic nervous system adrenergic pathways129 contribute to a vascular component 
to ischemic heart disease in women, although ill defined.
•   Microvascular dysfunction may add a significant component to IHD in women that is not easily assessed clinically.126,128
•   Ultrasound studies in obstructive CAD reveals greater microvascular disease in women and greater atheroma burden 
with diffuse epicardial endothelial dysfunction.130
•   endothelial dysfunction is raised in women with multiple risk factors and accelerates after menopause,131 by a factor 
of from 1.3 to 4.4.132
• increased number of endothelial progenitor cells after myocardial infarction.
•   in sudden coronary death, young women have a higher proportion of erosions than ruptures in culprit vessels.79
•   Aspirin lowers platelet reactivity similarly in men and women,133 but is less effective as primary prevention  
in women.134
•   Part of the protective effect of estrogen may be mediated by increased activity of serine/threonine protein kinase 
(Akt), which is involved in cell survival.
epidemiology • More women die from CAD than from cancer, with a ratio of 4.6 to 2.6.135
• CAD mortality reductions noted recently for women are lower than for men.136
• Compared to men, the absolute number of women dying from iHD is greater.
• About 52% of women, compared to 42% of men, die of SCD prior to arriving at a hospital.137
• Recent reductions in incidence of SCD reported in men are not enjoyed by women.138
• Some epidemiological differences are believed to be hormone related.
Pathophysiology • Microvascular dysfunction appears to be more significant in women.139
•   Obstructive CAD is less frequent, LVF better preserved,140 and rates of ischemia are higher in women than men in 
age­matched cohorts.116,140,141
•   Plaque instability, especially erosion and distal microembolization, is a greater factor in women in the evolution of 
coronary plaque.142,143
•   Cardiac remodeling in response to ischemic cell death, overload and age are different and is better than in men.
•   incidence, prevalence, and severity of heart failure is lower in women than men, possibly due to estrogen’s 
protective, anti-fibrotic, anti-inflammatory effects.
Risk factors •   Post menopausal rise in dyslipidemia,116,144,145 weight,146 and in the cluster of risk factors known as the MetS147,148 adds 
to the burden in women.
• Hypertriglyceridemia is more atherogenic in women than in men.149
• Diabetes raises CAD mortality to a greater extent in women than in men.150
• Recent reductions in CAD mortality observed in men with diabetes are not enjoyed by women.151
• Levels of CRP are higher in women than in men, beginning at puberty.152
• Benefits of statins, especially in prolonging life, continue to be debated.
Risk factor assessment • CRP is an important risk factor in women.135,136
• Framingham Risk Scores underestimate individual risk, but do so inordinately in women.153–156
•   inclusion of CRP in risk evaluation improves risk assessment in .40% of women classified as intermediate risk by 
Framingham Scores.157
Presentation • Atypical symptoms are more frequent in women,158 with reporting influenced by male dominated original studies.159
• women delay seeking medical care for angina160 and there is also a delay in door­to­hospital time.161,162
• Atypical presentations lead to lower calculated probabilities of obstructive CAD than in men.163
Natural history •   Symptoms are often more persistent,164 leading to higher hospital admission rates, including those for HF,165 incurring 
greater utilization and costs,166 thereby lowering quality of life.167
•   A higher prevalence of atypical chest pain together with negative studies may create ambiguity and indecision 
regarding diagnosis and treatment plans as compared to men.164,165
(Continued)Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 7 (Continued)
Category Finding or observation
exercise electrocardiography •   The exercise ECG has lower specificity and sensitivity in women,168 in part because the incidence of obstructive 
lesions is lower than in men.
• For each additional MeT in exercise capacity achieved in asymptomatic women being tested, mortality falls by 17%.169
• For each additional unit recorded in the Duke Treadmill Score, the risk of death falls by 9%.169
•   when women cannot exercise at levels of .5 MeT, which is not uncommon, risk of AMi or cardiac death rises 
about 3­fold.170,171
Cardiac imaging • Myocardial perfusion imaging and echocardiography raise diagnostic sensitivity as compared to the exercise eCG.102,172
•   Accuracy of SPeCT imaging is reduced when exercise capacity is low, and hence pharmacologic stress testing is 
recommended.98
•   Since specificity may be lowered by excess fat and breast tissue to produce false positive results, higher energy 99mTc 
or prone imaging minimizes artifact s and offers an advantage.103
•   Stress echocardiography is accurate diagnostically173 with a specificity of about 76% and sensitivity of about 84%, and 
can also used for risk stratification.174
Coronary angiography •   Nearly half the women who are studied have normal (,50% stenosis) coronary angiograms,175 which also applies to 
women with ACS.140 Over half of those women will continue to suffer with ischemic symptoms.
• Among STeMi patients, 10%–25% of women have normal angiograms, compared to 6%–10% of men.176,177
Treatment • women are undertreated both medically and procedurally with respect to current guidelines.161
• women are less likely to receive referrals to cardiologists by primary care providers.178
• women have greater mortality when undergoing PCi after myocardial infarctions.179
•   During medical treatment, women have more disability, lower quality of life, and poorer outcomes. This is partially 
due to bias in evaluation and treatment, but more because of innate biological differences between in men and 
women not yet fully appreciated.
• when it comes time to start or resume medications for secondary prevention, women are slighted.
Prognosis • Correction of endothelial dysfunction in postmenopausal hypertensive women may lower iHD events 7.3­fold.180
•   Older population, delay in presentation, less obstructive CAD, more risk factors, different testing characteristics, 
milder AMis with higher mortalities, underutilization of guideline recommendations, more microvascular dysfunction, 
increased adverse event rate after PCi, sex difference in biomarkers, greater mortality after PCi in low risk women, 
may all contribute to poorer prognosis in women than men.104
•   in chronic stable angina, as the eF decreases, as assessed with echocardiography, risk rises and mortality worsens 
faster in women than in men.181
•   women with obstructive CAD undergoing coronary angiography have about twice the odds of in­hospital death140 
and greater mortality after AMi.182
• CRP is an important risk factor in women.135,136
• Framingham Risk Scores underestimate individual risk, but do so inordinately in women.153–156
•   inclusion of CRP in risk evaluation improves risk assessment in .40% of women classified as intermediate risk by 
Framingham Scores.157
Note: *This table is by no means complete, and only contains a fraction of available resources.
Abbreviations: ACS, acute coronary syndrome; AMi, acute myocardial infarction; CRP, C­reactive protein; CAD, coronary artery disease; eF, ejection fraction; iHD,	
ischemic heart disease; HF, heart failure; LVF, left ventricular function; MeT, metabolic equivalent task; MetS, metabolic syndrome; SCD, sudden cardiac death; STeMi,   
ST­segment elevation myocardial infarction.
discomfort is a commonly encountered symptom reflecting 
myocardial ischemia. Successful management draws upon 
both the science and art of medicine, but yet may challenge 
even the most seasoned cardiologist. New pathophysiologi-
cal data, as well as conceptual and technological advances, 
have consistently improved patient evaluation over the past 
decade.
While perhaps less fashionable than topics concerning 
myocardial infarction/STEMI/NSTEMI, PCI, and CABG, 
the sheer number of patients afflicted with angina has 
attracted renewed interest. Independently, diagnosis, risk 
assessment, ability to predict prognosis, and treatment all 
remain imperfect.
Unfortunately, just as guideline defined targets remain 
unmet in the treatment of hypertension, dyslipidemia, and 
diabetes, significant numbers of women, and to a lesser 
degree, men, are also undertreated for their angina, and suffer 
ongoing, disabling exertional symptoms while under active 
medical care. Despite fundamental advances in basic science 
and availability of clinical outcome data, clinical inertia in 
following current guidelines continues to be a barrier in 
achieving therapeutic goals.
In the second part of this two-part series, current evidence 
based medical management with anti-ischemic therapy, 
promising novel anti-anginal agents and their potential to 
improve outcomes, options for treating refractory angina, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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the important role of implementing population-wide, lifestyle 
modification and risk reduction to lower the prevalence and 
burden of angina and ischemic heart disease, and current 
data, guidelines, and comparative performance regarding 
revascularization procedures in patients will be reviewed.
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